Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer

International Journal of Clinical Oncology

Volumn 18, Issue 3, 2013, Pages 435-438

  Hori, Natsuko ^a   Iwasa, Satoru ^a   Hashimoto, Hironobu ^a   Yanai, Takako ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Yamada, Yasuhide ^a   Murakoshi, Kouji ^a   Yokote, Nobuaki ^a   Yamamoto, Hiroshi ^a   Shimada, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Bevacizumab; Colorectal cancer; Contraindications; FOLFOX

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG CONTRAINDICATION; DRUG SAFETY; FEMALE; FINANCIAL MANAGEMENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; PROTEINURIA; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 84879415281     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0398-4     Document Type: Article

References (8)

1. Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
2. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779-4786
3. Tamiya A, Yamazaki K, Boku N et al (2009) Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol 14:513-517
4. Doi T, Boku N, Kato K et al (2010) Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 40:913-920
5. Kabbinavar F, Shah A (2008) Guidelines for the management of side effects of bevacizumab in patients with colorectal cancer. Cancer Therapy 6:327-340
6. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842-1847
7. Kozloff M, Yood MU, Berlin J et al (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14:862-870
8. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544